Literature DB >> 2293503

Transfusion-associated graft-versus-host disease.

J M Rappeport1.   

Abstract

The clinical pathologic syndrome of graft-versus-host disease (GVHD) is usually a sequela of bone marrow transplantation. This disorder occurs as a result of recognition by engrafted donor-derived lymphocytes of "foreign" recipient transplantation antigens. GVHD may also result from engraftment of lymphocytes from other sources, including (1) transfusion of lymphocytes containing blood components, (2) transplacental maternal fetal transfusion, and (3) passive transfer of lymphocytes in solid organ transplantation. The recipients are usually severely immunodeficient and thus incapable of rejecting the transfused lymphocytes. This syndrome may, however, also develop in immunologically competent patients receiving blood products from individuals with histocompatibility antigens not recognized as foreign.

Entities:  

Mesh:

Year:  1990        PMID: 2293503      PMCID: PMC2589351     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  50 in total

1.  Graft-versus-host reaction (GVHR). A case report suggesting GVHR occurred as a result of maternofetal cell transfer.

Authors:  T M Grogan; D D Broughton; W F Doyle
Journal:  Arch Pathol       Date:  1975-06

2.  Blood transfusion-induced suppression of delayed-type hypersensitivity to allogeneic histocompatibility antigens.

Authors:  A C Knulst; C Bazuin; R Benner
Journal:  Transplantation       Date:  1989-11       Impact factor: 4.939

3.  The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery.

Authors:  M Thaler; A Shamiss; S Orgad; M Huszar; N Nussinovitch; S Meisel; E Gazit; J Lavee; A Smolinsky
Journal:  N Engl J Med       Date:  1989-07-06       Impact factor: 91.245

4.  Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism.

Authors:  W Drobyski; S Thibodeau; R L Truitt; L A Baxter-Lowe; J Gorski; R Jenkins; J Gottschall; R C Ash
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

5.  Viability of platelets following storage in the irradiated state. A pair-controlled study.

Authors:  E J Read; C Kodis; C S Carter; S F Leitman
Journal:  Transfusion       Date:  1988 Sep-Oct       Impact factor: 3.157

6.  Fatal graft-vs.-host reaction following transfusion of allogeneic blood and plasma in infants with combined immunodeficiency disease.

Authors:  B H Park; R A Good; J Gate; B Burke
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

7.  Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation.

Authors:  H J Deeg; T C Graham; L Gerhard-Miller; F R Appelbaum; F Schuening; R Storb
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

8.  Granulocyte transfusions in treatment of infections in patients with acute leukaemia and aplastic anaemia.

Authors:  R M Lowenthal; L Grossman; J M Goldman; R A Storring; N A Buskard; D S Park; B C Murphy; A S Spiers; D A Galton
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

9.  Oxidative product formation in irradiated neutrophils. A flow cytometric analysis.

Authors:  R A Wolber; R E Duque; J P Robinson; H A Oberman
Journal:  Transfusion       Date:  1987 Mar-Apr       Impact factor: 3.157

10.  Fatal erythroderma (suspected graft-versus-host disease) after cholecystectomy. Retrospective analysis.

Authors:  S Otsuka; K Kunieda; M Hirose; H Takeuchi; Y Mizutani; M Nagaya; G Sato; S Kasuya; K Matsutomo; A Noma
Journal:  Transfusion       Date:  1989 Jul-Aug       Impact factor: 3.157

View more
  2 in total

1.  Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an immunocompetent patient.

Authors:  Ketan K Patel; Atul K Patel; Rajiv R Ranjan; Apurva P Shah
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-01       Impact factor: 0.900

2.  DNA-based HLA typing of nonhematopoietic tissue used to select the marrow transplant donor for successful treatment of transfusion-associated graft-versus-host disease.

Authors:  D F Friedman; P Kwittken; B Cizman; E Argyris; J Kearns; S Y Yang; C Zmijewski; N Bunin; S D Douglas; D Monos
Journal:  Clin Diagn Lab Immunol       Date:  1994-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.